We narrowed to 9,507 results for: try

1. pDONR221-SLC2A13_STOP

   Plasmid

   #161316

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC2A13 (SLC2A13 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available Since

   Oct. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

2. pDONR221-SLC35F1_STOP

   Plasmid

   #161299

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC35F1 (SLC35F1 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available Since

   Oct. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

3. pDONR221-SLC35E3_STOP

   Plasmid

   #161228

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC35E3 (SLC35E3 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available Since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

4. pDONR221-SLC2A12_STOP

   Plasmid

   #161233

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC2A12 (SLC2A12 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available Since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

5. pDONR221-SLC35D3_STOP

   Plasmid

   #161276

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC35D3 (SLC35D3 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available Since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

6. pDONR221-SLC41A2_STOP

   Plasmid

   #161320

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC41A2 (SLC41A2 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available Since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

7. pDONR221-UNC93A_STOP

   Plasmid

   #161448

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   UNC93A (UNC93A Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available Since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

8. pDONR221-SLC4A5_STOP

   Plasmid

   #161450

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC4A5 (SLC4A5 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available Since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

9. pDONR221-TMEM104_STOP

   Plasmid

   #161428

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   TMEM104 (TMEM104 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available Since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

10. pDONR221-SLC31A1_STOP

    Plasmid

    #161418

    Purpose

    Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

    Depositor

    Giulio Superti-Furga, RESOLUTE Consortium

    Article

    Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

    Insert

    SLC31A1 (SLC31A1 Human)
    

    Use

    Tags

    Expression

    Mammalian

    Mutation

    Promoter

    Available Since

    Sept. 15, 2021

    Availability

    Industry, Academic Institutions, and Nonprofits

    

    Enlarge